The Food and Drug Administration (FDA) approved Wegovy (semaglutide) in 2021 for chronic (long-term) weight management. In 2024, the FDA approved the drug for an additional use: to reduce the risk ...
The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company’s ambitions for a successor to its Wegovy weight-loss drug that is more powerful than Eli Lilly’s ...